Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-cash Items: 2020-2024

Historic Non-cash Items for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $37.3 million.

  • Apellis Pharmaceuticals' Non-cash Items fell 97.36% to $6.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year decrease of 97.36%. This contributed to the annual value of $37.3 million for FY2024, which is 85.31% down from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Non-cash Items is $37.3 million, which was down 85.31% from $253.9 million recorded in FY2023.
  • Apellis Pharmaceuticals' Non-cash Items' 5-year high stood at $253.9 million during FY2023, with a 5-year trough of $6.1 million in FY2020.
  • Its 3-year average for Non-cash Items is $100.0 million, with a median of $37.3 million in 2024.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Non-cash Items skyrocketed by 2,761.86% in 2023 and then tumbled by 85.31% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Non-cash Items (Yearly) stood at $6.1 million in 2020, then climbed by 27.00% to $7.7 million in 2021, then grew by 15.25% to $8.9 million in 2022, then surged by 2,761.86% to $253.9 million in 2023, then plummeted by 85.31% to $37.3 million in 2024.